HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A prospective multi-center trial of Escherichia coli extract for the prophylactic treatment of patients with chronically recurrent cystitis.

Abstract
We have assessed the efficacy and safety of Escherichia coli extract (ECE; Uro-Vaxom) which contains active immunostimulating fractions, in the prophylactic treatment of chronically recurrent cystitis. Forty-two patients with more than 2 episodes of cystitis in the proceeding 6 months were treated for 3 months with one capsule daily of ECE and observed for a further 6 months. The primary efficacy criterion was the number of episodes of recurrent cystitis during the 6 months after treatment compared to those during the 6 months before treatment. At the end of the 9-month trial, 34 patients (all women) were eligible for statistical analysis. Their mean age was 56.4 yr (range, 34-75 yr), and they had experienced recurrent urinary tract infections for 7.2+/-5.2 yr. The number of recurrences was significantly lower during the 6-month follow-up period than during the 6 months preceding the trial (0.35 vs. 4.26, P<0.001). During the follow-up, 28 (82.4%) patients had no recurrences and 4 (11.8%) had 1 each. In patients who relapsed, ECE alleviated cystitis symptoms, including painful voiding, frequency and urgency. There were no serious adverse events related to the study drug. Our study demonstrates the efficacy and safety of ECE in the prophylactic treatment of chronically recurrent cystitis.
AuthorsKun Suk Kim, Ji-Yoon Kim, In Gab Jeong, Jae-Seung Paick, Hwancheol Son, Dae Jung Lim, Hong Bang Shim, Won Hee Park, Hee Chang Jung, Myung-Soo Choo
JournalJournal of Korean medical science (J Korean Med Sci) Vol. 25 Issue 3 Pg. 435-9 (Mar 2010) ISSN: 1598-6357 [Electronic] Korea (South)
PMID20191044 (Publication Type: Clinical Trial, Journal Article, Multicenter Study)
Chemical References
  • Cell Extracts
Topics
  • Adult
  • Aged
  • Cell Extracts (immunology, therapeutic use)
  • Cystitis (drug therapy, immunology, microbiology, prevention & control)
  • Escherichia coli (chemistry, immunology, pathogenicity)
  • Female
  • Humans
  • Middle Aged
  • Prospective Studies
  • Recurrence

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: